Showing results (201-210 of 256) with videos related to

Sort By:
Pageof 26
Internal Medicine Journal|December 8, 2023
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy RegistryAnna Nelson, P Joy Ho, Helen Haysom, et al.
Internal Medicine Journal|January 8, 2026
Treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory GroupShirlene Sim, Georgia McCaughan, Andrew Zannettino, et al.
Blood|March 2, 2010
Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapyJia Li, Daniel M-Y Sze, Ross D Brown, et al.
Immunology and Cell Biology|January 22, 2016
A CD2 high-expressing stress-resistant human plasmacytoid dendritic-cell subsetChristian Bryant, Phillip D Fromm, Fiona Kupresanin, et al.
Internal Medicine Journal|May 6, 2025
Economic burden of sickle cell disease in AustraliaSteve Nwokeocha, Helen E Haysom, Cameron Wellard, et al.
Blood Advances|March 28, 2020
Targeting CD300f to enhance hematopoietic stem cell transplantation in acute myeloid leukemiaEdward Abadir, Pablo A Silveira, Robin E Gasiorowski, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Advances in Therapy|October 31, 2018
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple MyelomaXu Steven Xu, Meletios A Dimopoulos, Pieter Sonneveld, et al.
Blood Advances|November 9, 2020
Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaThierry Facon, Ruben Niesvizky, Maria-Victoria Mateos, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 19, 2019
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases RegistryP Joy Ho, Elizabeth M Moore, Zoe K McQuilten, et al.
Pageof 26